Searched for
LOWER DRUG PRICES
Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...- US stocks: US market ends lower as tech stocks weigh on sentimentWall Street ended lower on Friday, with AI chip stocks experiencing a significant downturn while Moderna and other healthcare companies sur...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- US probes Germany's drug pricing policies, opens door to tariffsThe US has launched a trade probe into Germany's pharmaceutical pricing, alleging it unfairly burdens American commerce and forces the US t...
- How many Americans can afford high-quality healthcare? A new poll finds the number has fallenAmericans face growing challenges affording healthcare. New data reveals a significant drop in those able to manage medical costs and acces...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Falling crude, stronger rupee could boost earnings outlook for India: Deepak ShenoyIndian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...
- How to remove pesticides naturally from your favourite summer fruits: Berries, peaches and plumsSummer's bounty of berries, peaches, and plums offers peak flavour and nutrition. While delicious, these fruits can carry pesticide residue...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Trump has a new, surprising take on the higher cost of living: 'I love the inflation'President Trump surprised many by stating he loves inflation. He linked rising prices to the Iran war. Trump also claimed secret military a...
- Infosys-backed 4baseCare raises Rs 128 crore, plans to take its cancer testing platform globalPrecision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...
- Market Trading Guide: Akums Drugs among 4 stock recommendations for ThursdayDomestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain ...
- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- US stocks: S&P 500, Nasdaq end up as tech, chipmakers reboundU.S. stocks largely rose Monday, with the Nasdaq and chipmakers leading the gains as investors sought bargains after Friday's selloff. Reli...
Load More
